WOBURN, Ma., Sept. 27, 2023 /PRNewswire/ -- Azurity Pharmaceuticals, Inc. ('Azurity') is pleased to announce the closing of its acquisition of Slayback Pharma LLC ('Slayback') today from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity..

马萨诸塞州沃本市，2023年9月27日/PRNewswire/-Azurity Pharmaceuticals，Inc。（'Azurity'）很高兴宣布今天从现有投资者中关闭Slayback Pharma LLC（'Slayback'），包括KKR，一家领先的全球投资公司和Everstone资本。Slayback现在是Azurity的合资子公司。。

The acquisition brings together companies with complementary strengths, enhancing Azurity's ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.

此次收购汇集了具有互补优势的公司，提高了Azurity实现服务被忽视患者目标的能力。预计合并的开发组合将在未来几年内产生大量新药推出。

Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust pipeline. The company's patient-centric approach is evident in its diverse array of products catering to various medical needs, including cardiovascular, central nervous system, endocrinological, gastrointestinal, anti-infectives and oncology.

Azurity利用其集成功能和庞大的合作伙伴网络，不断扩大其广泛的商业产品组合和强大的管道。该公司以患者为中心的方法在满足各种医疗需求的各种产品中表现明显，包括心血管，中枢神经系统，内分泌，胃肠，抗感染和肿瘤学。

Many of Azurity's medicines are dose-form innovations for patients with needs that are not met by other commercially available therapies..

Azurity的许多药物都是针对其他商业疗法无法满足需求的患者的剂型创新。。

'I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients,' said Richard Blackburn, CEO of Azurity. 'The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients.

“我很高兴宣布这种组合，并为被忽视的患者带来更多的潜力，”Azurity首席执行官理查德布莱克本说两家公司在开发创新剂型方面的互补专业知识将形成强大的新药渠道，以满足患者的需求。

We will bring the commercial expertise of Azurity to Slayback's pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs.'.

我们将把Azurity的商业专业知识带到Slayback的管道中，并期待推出更广泛的剂型和配方，以满足更广泛的患者需求。

'The combination of Slayback and Azurity is a union of highly complementary capabilities: Azurity's innovative commercial acumen and Slayback's exceptional R&D platform. I am proud of Slayback's team, our track record of developing complex products with unmatched speed at scale, and the rich history we have built together.

“Slayback和Azurity的结合是高度互补功能的结合：Azurity创新的商业敏锐度和Slayback卓越的研发平台。我为Slayback的团队感到自豪，我们在规模上以无与伦比的速度开发复杂产品的记录，以及我们建立在一起的丰富历史。

I am delighted to join forces with Azurity to help forge a combined entity that is truly one of a kind,' added Ajay Singh, Founder and CEO of Slayback..

Slayback的创始人兼首席执行官Ajay Singh补充说，我很高兴与Azurity合作，帮助组建一个真正属于一种的联合实体。。

'We are pleased to add Slayback's complementary product pipeline and robust R&D capabilities to Azurity. The acquisition of Slayback accelerates Azurity's strategic growth plan and enhances our ability to launch multiple innovative new drug products into the market every year to serve overlooked patients,' said Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity..

“我们很高兴为Azurity添加Slayback的补充产品管道和强大的研发功能。收购Slayback加速了Azurity的战略增长计划，并提高了我们每年向市场推出多种创新新药产品以服务被忽视患者的能力，“Azurity的多数所有者QHP Capital的合作伙伴杰夫爱德华兹说。。

'We have enjoyed working closely with Ajay and Slayback's impressive management team to scale and support the platform as a leading provider of complex pharmaceuticals,' said Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR. 'Together we have established an extensive pipeline that Azurity will further build upon, helping to increase accessibility to health care for patients.' .

“我们很高兴与Ajay和Slayback令人印象深刻的管理团队密切合作，扩大和支持该平台作为复杂药物的领先供应商，”KKR合作伙伴和全球医疗保健战略增长负责人Ali Satvat说我们共同建立了一条广泛的管道，将进一步巩固天青，有助于增加患者获得医疗保健的机会 .

Greenhill & Co. served as financial advisor and White & Case served as legal advisor to Azurity. Leerink Partners served as lead financial advisor and Raymond James as co-advisor to Slayback while Kirkland & Ellis served as legal advisor to Slayback.

Greenhill＆Co。担任财务顾问，White＆Case担任Azurity的法律顾问。Leerink Partners担任首席财务顾问，Raymond James担任Slayback的共同顾问，而Kirkland＆Ellis担任Slayback的法律顾问。

About Azurity Pharmaceuticals:Azurity is a privately-held pharmaceutical company specializing in providing innovative, high-quality medicines that serve overlooked patients. Azurity supplies a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines.

关于Azurity Pharmaceuticals:Azurity是一家私营制药公司，专门为被忽视的患者提供创新的高质量药物。Azurity提供大量产品来治疗各种医疗条件。这些包括心血管，中枢神经系统，内分泌，胃肠，抗感染和肿瘤药物。

Many of Azurity's medicines are dose-form innovations for patients with needs that are not met by other available products. Azurity's medicines have benefited millions of people. For more information, please visit www.azurity.com..

Azurity的许多药物都是针对其他可用产品无法满足需求的患者的剂型创新。Azurity的药物使数百万人受益。欲了解更多信息，请访问www.azurity.com。。

About QHP Capital:QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP traces its heritage back to Quintiles (now IQVIA) and NovaQuest Capital Management. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams.

关于QHP资本：QHP资本是生命科学和医疗保健领域技术和服务公司的投资者。QHP将其遗产追溯到五分位数（现为IQVIA）和NovaQuest资本管理。QHP建立了一个投资平台，与强大的管理团队合作，提供战略资本和行业专业知识。

The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science and healthcare expertise. QHP benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing QHP's portfolio companies.

投资团队由经验丰富的投资和运营专业人员组成，具有丰富的投资经验和深刻的生命科学和医疗保健专业知识。QHP受益于广泛的行业专家和关系网络，有助于识别，分析和增长QHP的投资组合公司。

QHP also manages the NovaQuest Private Equity funds. For more information, please visit www.qhpcapital.com..

QHP还管理NovaQuest私募股权基金。欲了解更多信息，请访问www.qhpcapital.com。。

SOURCE Azurity Pharmaceuticals

来源Azurity制药